IMM vs. SBTX, ETX, TRX, COS, FUM, C4XD, DDDD, OKYO, AOR, and AREC
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include SkinBioTherapeutics (SBTX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), Futura Medical (FUM), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), AorTech International (AOR), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry.
ImmuPharma vs.
ImmuPharma (LON:IMM) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
ImmuPharma has a net margin of 3,519.56% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat ImmuPharma's return on equity.
ImmuPharma received 219 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
17.4% of ImmuPharma shares are owned by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 48.3% of ImmuPharma shares are owned by insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ImmuPharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
ImmuPharma has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, SkinBioTherapeutics had 2 more articles in the media than ImmuPharma. MarketBeat recorded 2 mentions for SkinBioTherapeutics and 0 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.00 beat SkinBioTherapeutics' score of -1.09 indicating that ImmuPharma is being referred to more favorably in the media.
Summary
ImmuPharma beats SkinBioTherapeutics on 10 of the 15 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy IMM Stock Free IMM Stock Alerts